24/7 Market News Snapshot 14 July, 2025 – Avalon GloboCare Corp. Common Stock (NASDAQ:ALBT)

July 14, 2025

DENVER, Colo., 14 July, 2025 (www.247marketnews.com) – (NASDAQ:ALBT) are discussed in this article.
Avalon GloboCare Corp. (NASDAQ:ALBT) is experiencing a remarkable surge in its stock performance, with shares trading at $4.558, reflecting a substantial 78.75% increase from the previous closing price of $2.550 during pre-market hours. This remarkable uptick signifies heightened investor confidence, illustrated by an impressive trading volume surpassing 5.93 million shares. The burgeoning interest suggests a critical point for investors looking to leverage potential gains, as the stock breaks through significant resistance levels.

In addition to the favorable market movement, Avalon has recently achieved a significant milestone by securing a pivotal standard patent from the Hong Kong Intellectual Property Department (HKIPD) for its advanced chimeric antigen receptor (CAR) therapies, specifically CAR-T and CAR-Natural Killer (NK) cell technologies. Officially registered as patent number HK40074322, this innovation is set to be protected for a duration of 20 years starting from February 21, 2020. The patent not only strengthens Avalon’s intellectual property portfolio but also enhances its competitive edge in the rapidly evolving domain of cell-based immunotherapy, complementing similar protections under the Patent Cooperation Treaty (PCT) and in the United States.

Co-developed with strategic partner Arbele Limited, this patented technology introduces significant advancements, including a Bispecific Anti-CD19xCD22 CAR Design aimed at reducing tumor escape probabilities and a Localized Cytokine Induction mechanism designed to enhance immune responses at tumor sites. This breakthrough positions Avalon as a frontrunner in addressing critical treatment challenges associated with hematologic malignancies.

David Jin, M.D., Ph.D., CEO of Avalon, expressed palpable enthusiasm regarding the patent grant, viewing it as a strategic endeavor that underscores Avalon’s commitment to pioneering advancements in medical technology, ultimately aimed at improving patient outcomes on a global scale.

Related news for (ALBT)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.